Company news

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) news

Verrica Pharmaceuticals Inc. news releases on 6ix. Latest, Sep 30, 2026: Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming…

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) news

Press releases & updates

Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences

Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences

Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results

Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026

Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer

Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway

Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results

Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting

Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union

Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025

Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors

Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston

Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference

Verrica Provides Business and Operational Update

Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

Verrica Announces Pricing of $42.0 Million Public Offering